Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics

by Karachaliou N, Rosell R
Published 2014-11-01

Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives

by Karachaliou N, Fernandez Bruno M, Bracht JWP, Rosell R
Published 2019-06-01

Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice

by Passaro A, Lazzari C, Karachaliou N, Spitaleri G, Pochesci A, Catania C, Rosell R, de Marinis F
Published 2016-10-01

Response to crizotinib in a non-small-cell lung cancer patient harboring an EML4-ALK fusion with an atypical LTBP1 insertion

by Aguado C, Gil MDLL, Yeste Z, Giménez-Capitán A, Teixidó C, Karachaliou N, Viteri S, Rosell R, Molina-Vila MA
Published 2018-03-01

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy

by Santarpia M, Liguori A, Karachaliou N, Gonzalez-Cao M, Daffinà MG, D'Aveni A, Marabello G, Altavilla G, Rosell R
Published 2017-08-01

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy

by Santarpia M, Daffinà MG, D'Aveni A, Marabello G, Liguori A, Giovannetti E, Karachaliou N, Gonzalez Cao M, Rosell R, Altavilla G
Published 2017-07-01

Targeting PD-1/PD-L1 in lung cancer: current perspectives

by González-Cao M, Karachaliou N, Viteri S, Morales-Espinosa D, Teixidó C, Sánchez Ruiz J, Molina-Vila MÁ, Santarpia M, Rosell R
Published 2015-07-01